Plain-English translation of NCT06780787 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for people with localized rectal cancer (cancer that hasn't spread beyond the rectum). The study combines three components—FOLFOX (chemotherapy), , and (newer immunotherapy drugs)—given intravenously before surgery. The goal is to see if this combination can shrink the tumor enough so that surgery is more effective and patients have better long-term outcomes.
Current standard treatment for rectal cancer involves chemotherapy and radiation followed by surgery, but doctors want to find ways to improve cure rates and reduce the chance of cancer coming back. This medication combination may work better by attacking the cancer in multiple ways at once.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions every two weeks for up to 8 cycles (about 4 months total), with each treatment day lasting several hours. You'll have regular blood draws, imaging scans (CT and MRI), and endoscopic exams to monitor how your tumor is responding. If the medication works well and your tumor shrinks completely, you may continue with one of the medications alone for several more months. If it doesn't shrink enough, you'll move on to standard radiation and oral chemotherapy before surgery, as is typical.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States